The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Alveolar hemorrhage, diffuse (ANCA-positive/-related)
Publications
Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.
BMJ case reports 2023 Jul 10;16; — 2023 Jul 10
Use of the Allium Round Posterior Stent for the Treatment of Recurrent Vesicourethral Anastomosis Stricture.
Urology 2023 Jul 08;; — 2023 Jul 08
Hydralazine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Case Report and Literature Review.
Cureus 2022 Apr;14;e24132 — 2022 Apr — e24132
Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use.
Cureus 2021 Oct;13;e18974 — 2021 Oct — e18974
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Current cardiology reviews 2020 May 17;; — 2020 May 17
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2019 Jan-Feb;30;226-230 — 2019 Jan-Feb — 226-230
Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome.
Case reports in nephrology 2014;2014;868590 — 2014 — 868590
Hydralazine-induced pulmonary-renal syndrome: a case report.
American journal of therapeutics 2012 Jul;19;e136-8 — 2012 Jul — e136-8